Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PF-03893787 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| PF-03893787 | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Montelukast | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| PF-03893787 | DRUG | Oral, two doses 12 hours apart |
| Placebo | DRUG | Oral, two doses 12 hours apart |
| Montelukast | DRUG | Oral, two doses 12 hours apart |
Inclusion Criteria: * Males and females 18-60 years. * Mild asthma * Atopic to allergens Exclusion Criteria: * Unstable asthma. * Smokers or recent ex-smokers * Recent allergen challenge
Top 16 of 18 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Novartis AG Sponsored ADR | NVS | 5 | PHASE3 | QVM149, QMF149, Glycopyrronium bromide |
| GSK plc Sponsored ADR | GSK | 10 | PHASE3 | Trelegy Ellipta, Depemokimab, HFA-152a, GSK5784283, Ventolin |
| Teva Pharmaceutical Industries Limited Sponsored ADR | TEVA | 4 | PHASE3 | TEV-56248, ProAir (albuterol sulfate eMDPI), Budesonide/Formoterol SPIROMAX, Reslizumab |
| Sanofi SA Sponsored ADR | SNY | 8 | PHASE3 | Dupilumab, Lunsekimig |
| AstraZeneca PLC | AZN | 28 | PHASE3 | Benralizumab, Tezepelumab, Budesonide/formoterol, Albuterol/budesonide, PT007 |
| Pfizer Inc. | PFE | 4 | PHASE3 | Tilrekimig, PF-07275315, PF-08103402 |
| Generate Biomedicines, Inc. | GENB | 3 | PHASE3 | GB-0895 |
| Kymera Therapeutics, Inc. | KYMR | 1 | PHASE2 | KT-621 |
| Eli Lilly and Company | LLY | 1 | PHASE2 | Brenipatide |
| Incyte Corporation | INCY | 1 | PHASE2 | povorcitinib |
| Upstream Bio, Inc. | UPB | 1 | PHASE2 | Verekitug |
| Arrowhead Pharmaceuticals, Inc. | ARWR | 1 | PHASE2 | ARO-RAGE |
| Amgen Inc. | AMGN | 1 | PHASE1 | AMG 691 |
| Johnson & Johnson | JNJ | 1 | PHASE2 | JNJ-95597528 |
| Apogee Therapeutics, Inc. | APGE | 1 | PHASE1 | APG777 |
| Celldex Therapeutics, Inc. | CLDX | 1 | PHASE1 | CDX-622 |
PF-03893787 is an investigational small molecule developed by Pfizer, Inc. for the treatment of asthma, a respiratory condition. It was studied in a Phase 1 clinical trial that has been completed. It is not an approved therapy and remains in clinical development.
PF-03893787 was studied for use in asthma, with the goal of assessing its effect on lung function following an allergen challenge in asthmatic subjects. The trial enrolled 12 adults with asthma in the United Kingdom. It is an investigational agent and is not approved for the treatment of asthma.
PF-03893787 is developed by Pfizer, Inc., which trades on the New York Stock Exchange under the ticker PFE. Pfizer sponsored the Phase 1 study of the compound in asthma. No other developer or partner is associated with the asset in the available trial record.
PF-03893787 is in Phase 1 development. Its only recorded clinical trial was a Phase 1 study in asthma that has been completed. The drug is investigational and has not been approved by the FDA or any other regulatory agency for any indication.
PF-03893787 has been studied in one clinical trial, NCT00856687, titled A Study To Assess The Effect Of PF-03893787 On Lung Function Following An Allergen Challenge In Asthmatic Subjects. The Phase 1 trial was completed, enrolled 12 participants, and took place in the United Kingdom.
The Phase 1 trial of PF-03893787, NCT00856687, was a randomized, double-blind, placebo-controlled study in adults with asthma. It enrolled 12 participants aged 18 years and older of any sex, and it did not use healthy volunteers. The study was conducted in the United Kingdom and has been completed.